EDITAS MEDICINE, INC. Diluted Shares Outstanding (Weighted Average)
EDITAS MEDICINE, INC. (EDIT) reported Diluted Shares Outstanding (Weighted Average) of 119.29 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-05
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 119.29M shares, a 41.32% increase year-over-year.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 97.88M shares, a 17.85% increase year-over-year.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 97.35M shares, a 17.83% increase year-over-year.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 90.09M shares, a 9.22% increase year-over-year.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 88.75M shares, a 7.78% increase from fiscal 2024.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 82.34M shares, a 8.39% increase from fiscal 2023.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 75.97M shares, a 10.63% increase from fiscal 2022.
- EDITAS MEDICINE, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 68.66M shares, a 1.55% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 119.29M shares 10-Q · filed 2026-08-05 | 108.65M shares 10-Q · filed 2026-08-05 | 104.84M shares derived: average of 3 quarters · filed 2026-08-05 | 101.15M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 97.88M shares 10-Q · filed 2026-05-05 | 97.61M shares derived: average of 2 quarters · filed 2026-05-05 | 95.11M shares derived: average of 3 quarters · filed 2026-05-05 | 92.43M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 97.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 93.72M shares derived: average of 2 quarters · filed 2026-03-09 | 90.62M shares derived: average of 3 quarters · filed 2026-08-05 | 88.75M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 90.09M shares 10-Q · filed 2025-11-10 | 87.25M shares derived: average of 2 quarters · filed 2026-08-05 | 85.88M shares 10-Q · filed 2025-11-10 | 85.04M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 84.41M shares 10-Q · filed 2026-08-05 | 83.74M shares 10-Q · filed 2026-08-05 | 83.36M shares derived: average of 3 quarters · filed 2026-08-05 | 83.14M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 83.06M shares 10-Q · filed 2026-05-05 | 82.84M shares derived: average of 2 quarters · filed 2026-05-05 | 82.72M shares derived: average of 3 quarters · filed 2026-05-05 | 82.62M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 82.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 82.55M shares derived: average of 2 quarters · filed 2026-03-09 | 82.47M shares derived: average of 3 quarters · filed 2026-03-09 | 82.34M shares 10-K · filed 2026-03-09 |
| 2024-09-30 | 82.49M shares 10-Q · filed 2025-11-10 | 82.40M shares derived: average of 2 quarters · filed 2025-11-10 | 82.25M shares 10-Q · filed 2025-11-10 | 82.13M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | 82.31M shares 10-Q · filed 2025-08-12 | 82.12M shares 10-Q · filed 2025-08-12 | 82.01M shares derived: average of 3 quarters · filed 2025-08-12 | 81.92M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 81.94M shares 10-Q · filed 2025-05-12 | 81.86M shares derived: average of 2 quarters · filed 2025-05-12 | 81.79M shares derived: average of 3 quarters · filed 2025-05-12 | 79.18M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 81.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | 81.71M shares derived: average of 2 quarters · filed 2025-03-05 | 78.27M shares derived: average of 3 quarters · filed 2025-03-05 | 75.97M shares 10-K · filed 2025-03-05 |
| 2023-09-30 | 81.65M shares 10-Q · filed 2024-11-04 | 76.51M shares derived: average of 2 quarters · filed 2024-11-04 | 74.03M shares 10-Q · filed 2024-11-04 | 72.69M shares derived: average of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | 71.38M shares 10-Q · filed 2024-08-07 | 70.16M shares 10-Q · filed 2024-08-07 | 69.70M shares derived: average of 3 quarters · filed 2025-03-05 | 69.46M shares derived: average of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | 68.92M shares 10-Q · filed 2024-05-08 | 68.86M shares derived: average of 2 quarters · filed 2025-03-05 | 68.82M shares derived: average of 3 quarters · filed 2025-03-05 | 68.77M shares derived: average of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | 68.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | 68.77M shares derived: average of 2 quarters · filed 2025-03-05 | 68.72M shares derived: average of 3 quarters · filed 2025-03-05 | 68.66M shares 10-K · filed 2025-03-05 |
| 2022-09-30 | 68.74M shares 10-Q · filed 2023-11-03 | 68.69M shares derived: average of 2 quarters · filed 2023-11-03 | 68.62M shares 10-Q · filed 2023-11-03 | 68.56M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | 68.64M shares 10-Q · filed 2023-08-02 | 68.56M shares 10-Q · filed 2023-08-02 | 68.50M shares derived: average of 3 quarters · filed 2024-02-28 | 68.43M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | 68.48M shares 10-Q · filed 2023-05-05 | 68.42M shares derived: average of 2 quarters · filed 2024-02-28 | 68.36M shares derived: average of 3 quarters · filed 2024-02-28 | 68.24M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | 68.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 68.29M shares derived: average of 2 quarters · filed 2024-02-28 | 68.15M shares derived: average of 3 quarters · filed 2024-02-28 | 67.62M shares 10-K · filed 2024-02-28 |
| 2021-09-30 | 68.22M shares 10-Q · filed 2022-11-02 | 68.05M shares derived: average of 2 quarters · filed 2022-11-02 | 67.37M shares 10-Q · filed 2022-11-02 | 66.10M shares derived: average of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | 67.88M shares 10-Q · filed 2022-08-03 | 66.94M shares 10-Q · filed 2022-08-03 | 65.39M shares derived: average of 3 quarters · filed 2023-02-22 | 64.72M shares derived: average of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | 65.99M shares 10-Q · filed 2022-05-04 | 64.15M shares derived: average of 2 quarters · filed 2023-02-22 | 63.66M shares derived: average of 3 quarters · filed 2023-02-22 | |
| 2020-12-31 | 62.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | 62.50M shares derived: average of 2 quarters · filed 2023-02-22 | 58.61M shares 10-K · filed 2023-02-22 | |
| 2020-09-30 | 62.70M shares 10-Q · filed 2021-11-09 | 57.38M shares 10-Q · filed 2021-11-09 | ||
| 2019-12-31 | 52.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 51.01M shares derived: average of 2 quarters · filed 2022-02-24 | 49.98M shares 10-K · filed 2022-02-24 | |
| 2019-09-30 | 49.82M shares 10-Q · filed 2020-11-06 | 49.25M shares 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |